Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Common Vraylar (cariprazine) side effects include restlessness or an urge to move (akathisia), tremor, muscle stiffness, drowsiness or insomnia, nausea, vomiting, indigestion, constipation, increased appetite, weight gain, and anxiety, while less common but serious effects can involve uncontrollable movements (tardive dyskinesia), high blood sugar, high fever with confusion, fainting, or unusual mood changes. Many of these effects depend on your dose, how long you have been taking it, and what other medications or conditions you have, and because Vraylar stays in the body for weeks, reactions can appear or linger after a dose change, so review the full details below before assuming a symptom is harmless.
If you are unsure whether what you are feeling is an expected adjustment period or a warning sign that needs prompt medical attention, a free, instant, online symptom check can help you sort out the possibilities in just a few minutes. It asks the same kinds of questions a clinician would, then points you toward the level of care that fits your situation, which is especially useful when side effects overlap with the very symptoms you are treating. Bring those results to your prescriber so you can make an informed decision together instead of stopping or adjusting Vraylar on your own.
Last reviewed for medical accuracy: 09/24/2026
Understanding Vraylar and Its Side Effects
Vraylar (cariprazine) is an antipsychotic medication commonly prescribed to treat conditions like schizophrenia and bipolar I disorder. While many people benefit from improved mood stability, reduced hallucinations, or fewer manic episodes, it’s important to know about potential Vraylar side effects. This guide covers what you might experience, how to manage common reactions, and when to seek medical help.
Most people on Vraylar experience mild to moderate side effects that often improve over time. If these effects persist or worsen, let your doctor know.
These reactions are less frequent but worth watching:
While rare, some Vraylar side effects can be severe. If you experience any of these, seek medical attention immediately:
If you’re experiencing new or worsening symptoms and want a quick assessment, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide whether to seek immediate care or discuss concerns with your provider.
Always keep an open dialogue with your healthcare team. When discussing vraylar side effects, be prepared to share:
Your doctor might adjust your dose, switch medications, or recommend supportive therapies (like counseling, physical therapy for stiff muscles, or dietary changes).
Some reactions can be life threatening. If you notice:
Call emergency services or go to the nearest ER immediately.
Your health and safety come first. Never hesitate to reach out to your healthcare provider if you have concerns about vraylar side effects.
(References)
* Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777. doi: 10.2147/TCRM.S117321. Epub 2017 Jun 29. PMID: 28721057; PMCID: PMC5499790.
* Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14. PMID: 29536616; PMCID: PMC5947163.
* Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020 Jan;7(1):64-77. doi: 10.1016/S2215-0366(19)30416-X. Epub 2019 Dec 17. PMID: 31860457; PMCID: PMC7029416.
* Wu H, Siafis S, Hamza T, Schneider-Thoma J, Davis JM, Salanti G, Leucht S. Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. Schizophr Bull. 2022 May 7;48(3):643-654. doi: 10.1093/schbul/sbac001. PMID: 35137229; PMCID: PMC9077426.
* Schneider-Thoma J, Chalkou K, Dörries C, Bighelli I, Ceraso A, Huhn M, Siafis S, Davis JM, Cipriani A, Furukawa TA, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022 Feb 26;399(10327):824-836. doi: 10.1016/S0140-6736(21)01997-8. PMID: 35219395.
* Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. Int J Mol Sci. 2022 Sep 13;23(18). doi: 10.3390/ijms231810624. Epub 2022 Sep 13. PMID: 36142523; PMCID: PMC9500595.
* Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, Schneider-Thoma J, Davis JM, Leucht S. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023 Aug;28(8):3267-3277. doi: 10.1038/s41380-023-02203-y. Epub 2023 Aug 3. PMID: 37537284; PMCID: PMC10618092.
* Yildiz A, Siafis S, Mavridis D, Vieta E, Leucht S. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2023 Sep;10(9):693-705. doi: 10.1016/S2215-0366(23)00199-2. PMID: 37595997.
* DeBattista C, Schatzberg AF. The Black Book of Psychotropic Dosing and Monitoring. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. doi: 10.64719/pb.4493. PMID: 38993656; PMCID: PMC11235576.
* Koziej S, Kowalczyk E, Soroka E. Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential. Med Sci Monit. 2024 Sep 20;30:e945411. doi: 10.12659/MSM.945411. Epub 2024 Sep 20. PMID: 39300746; PMCID: PMC11421304.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.